Werewolf Therapeutics, Inc.
For the period ended Mar 31, 2026. Filed May 7, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 7, 2026
HOWL$0.97-4.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations for the and
Condensed Consolidated Statements of Operations (unaudited)
(amounts in thousands, except share and per share amounts)
| Three Months EndedMarch 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Operating expenses: | ||
| Research and development | $8,181 | $13,120 |
| General and administrative | 5,090 | 4,871 |
| Total operating expenses | 13,271 | 17,991 |
| Operating loss | (13,271) | (17,991) |
| Other expense: | ||
| Interest income | 433 | 997 |
| Interest expense | (1,368) | (1,263) |
| Other income, net | 674 | 168 |
| Total other expense | (261) | (98) |
| Net loss | $(13,532) | $(18,089) |
| Net loss per common share, basic | $(0.28) | $(0.40) |
| Net loss per common share, diluted | $(0.28) | $(0.40) |
| Weighted-average common shares outstanding, basic | 48,596,817 | 44,827,159 |
| Weighted-average common shares outstanding, diluted | 49,388,181 | 44,827,159 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.